Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB4 | Q16877 | 8/20 | 0.74 |
| ▸ | PFKFB3 | Q16875 | 11/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9997182 | 0.86 | PFKFB4 (0.74) | PFKFB4PFKFB3ALDH1A1HSD17B10MCL1 | |
| SCHEMBL788176 | 0.85 | PFKFB4 (1.00) | PFKFB4PFKFB3ALDH1A1FABP4 | |
| SCHEMBL788343 | 0.81 | PFKFB4 (1.00) | PFKFB4PFKFB3CMA1FABP4 | |
| SCHEMBL9996999 | 0.79 | PFKFB3 (0.63) | PFKFB4PFKFB3ALDH1A1HSD17B10MCL1 | |
| SCHEMBL9997467 | 0.76 | PFKFB3 (0.65) | PFKFB4PFKFB3ALDH1A1HSD17B10CMA1 | |
| SCHEMBL9997390 | 0.76 | PFKFB3 (0.65) | PFKFB3ALDH1A1HSD17B10MCL1FABP4 | |
| SCHEMBL9997294 | 0.75 | FABP4 (0.74) | PFKFB3ALDH1A1HSD17B10MCL1FABP4 | |
| SCHEMBL9996951 | 0.74 | PFKFB3 (0.84) | PFKFB4PFKFB3HSD17B10CMA1 | |
| SCHEMBL9997094 | 0.73 | PFKFB3 (0.71) | PFKFB4PFKFB3ALDH1A1HSD17B10CMA1 | |
| SCHEMBL9996808 | 0.72 | PFKFB3 (0.59) | PFKFB4PFKFB3ALDH1A1HSD17B10MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | claimed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | PFKFB4 2/4885PFKFB3 1/4885ALDH1A1 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.